Latest market price
26.20
-28.78-52.35%
OverviewShort InterestFilings
DRUGQT9Bright Minds Biosciences Inc.·NASDAQ
26.20-52.35%
News
Down 52.3% — Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-2.00Insider Own10.74%Shs Outstand9.86MPerf Week-48.72%
Market Cap258.44MForward P/E—EPS next Y-7.34Insider Trans—Shs Float6.74MPerf Month-48.31%
Enterprise Value41.44MPEG—EPS next Q-0.82Short Float12.32%Perf Quarter-66.13%
Income-18.00MP/S—EPS this Y—Short Ratio5.67Perf Half Y-68.53%
Sales0.00P/B1.19EPS next Y—ROA-7.96%Short Interest829.72KPerf YTD-66.43%
Book/sh22.00P/C1.19EPS next 5Y—ROE-12.56%52W High123.76 -78.83%Perf Year-51.90%
Cash/sh22.00P/FCF—EPS past 3/5Y—ROIC-12.92%52W Low18.90 38.62%Perf 3Y1768.89%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility8.29% 7.46%Perf 5Y-21.91%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)5.82Perf 10Y—
Dividend Ex-Date—Quick Ratio121.97Sales Y/Y TTM—Profit Margin0.00%RSI (14)22.75Recom2.00
Dividend Gr. 3/5Y—Current Ratio121.97EPS Q/Q67.92%SMA20-49.17%Beta-4.37Target Price—
Payout0.00%Debt/Eq0.00Sales Q/Q—SMA50-54.95%Rel Volume12.00Prev Close54.98
Employees26LT Debt/Eq0.00EarningsDec 22SMA200-64.08%Avg Volume151.84KPrice26.20
IPO DateMar 22, 2021Option/ShortNo / YesEPS/Sales Surpr.87.09% —Net Debt/EBITDA—Volume1,822,698Change-52.35%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-02-26ReiteratedBTIGBuy$37
Oct-15-26InitiatedWolfe ResearchOutperform
Jun-01-26ReiteratedHC Wainwright & Co.Buy$85
May-20-26ReiteratedPiper SandlerOverweight
Feb-13-26ReiteratedRobert W. Baird
Jan-07-26ReiteratedRobert W. Baird$82
Jan-07-26ReiteratedBTIGBuy
Jan-06-26ReiteratedBTIGBuy
May-07-25InitiatedChardanBuy$80
Jan-10-25InitiatedH.CBuy$85
Latest News· Times ET
Nov-02-26
Nov-02-2606:26PM
Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)prnewswire.com
07:30AM
Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathiesglobenewswire.com
Oct-29-26
Oct-29-2601:10PM
Top 3 Canadian Biotech Stocks To Watch In October 2026Yahoo
Oct-26-26
Oct-26-2604:40PM
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAMprnewswire.com
Oct-22-26
Oct-22-2612:14PM
3 Canadian Biotech Stocks With Up To 39% Net MarginsYahoo
Oct-15-26
Oct-15-2606:10AM
3 Canadian Biotech Stocks Trading Up To 93% Below Fair ValueYahoo
Oct-08-26
Oct-08-2605:09AM
Bright Minds Biosciences And 2 More Canadian Biotech StocksYahoo
Sep-30-26
Sep-30-2605:30PM
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conferenceglobenewswire.com
Sep-15-26
Sep-15-2608:46PM
3 Small Cap Stocks With Strong Revenue Growth And Low DebtYahoo
Sep-04-26
Sep-04-2604:30PM
Bright Minds Biosciences to Present at Upcoming Conferencesglobenewswire.com
Aug-27-26
Aug-27-2601:00PM
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?zacks.com
Aug-26-26
Aug-26-2610:55AM
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?zacks.com
Aug-19-26
Aug-19-2607:12AM
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price TargetBenzinga
Aug-17-26
Aug-17-2608:24AM
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price TargetBenzinga
Aug-10-26
Aug-10-2610:57AM
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Betzacks.com
Company

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
Total Revenue
0000————
Cost of Goods Sold Incl. D&A
0000————
Gross Profit
0000————
Selling, General and Administrative Excl. Other6212————
Research and Development24814————
Other Operating Expense-200-1————
Operating Income-28-10-2-5————
Interest Expense
0000————
Unusual Expense
————————
Non-Operating Income (Expense)12100————
Net Income Before Taxes-18-9-2-5————
Income Taxes
0000————
Consolidated Net Income-18-9-2-5————
Net Income From Continuing Operations-18-9-2-5————
Net Income-18-9-2-5————
EPS (Recurring)-2.00-1.27-0.48-1.47————
EPS (Basic, Before Extraordinaries)-2.00-1.27-0.48-1.47————
EPS (Diluted)-2.00-1.27-0.48-1.47————
EBITDA-24-9-2-5————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
————————
Gross Margin
————————
Operating Margin
————————
Net Margin
————————
Shares Outstanding10744————
Market Capitalization26242556————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$106.46$83.78$61.09$38.41$15.73● Close Price0.00M2.45M4.89M7.34M9.79MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cormorant Asset Management, LPFormer 10% OwnerApr 28 '26Sale89.50109,3319,785,125950,000Apr 30
Cormorant Asset Management, LP10% OwnerNov 04 '24Buy21.70184,3313,999,9831,059,331Nov 06
Cormorant Asset Management, LP10% OwnerOct 16 '24Buy23.4650,0001,172,814875,000Oct 17
Cormorant Asset Management, LP10% OwnerOct 15 '24Buy5.53372,5912,061,573825,000Oct 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.